Skip to main content
    R

    Rallybio Corp (RLYB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.43
    -0.30 (-1.88%)

    Market Cap: $88.03M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Rallybio Corp (RLYB) Financials: Revenue, Profit and Cash Flow

    Updated Oct 27, 2026. Financial statements from company filings, amounts in US dollars.

    Rallybio reported revenue of $858.00K for the fiscal year ended Dec 31, 2025, up 34.9% from the year before. That year, net income was -$8.98M with a net margin of -1046.4%, operating cash flow was -$29.81M and free cash flow was -$29.81M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$2.73M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$858.00K+34.9%100.0%-3853.6%-1046.4%
    Dec 2024$636.00KN/A100.0%-9511.9%-9084.1%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$858.00K$636.00K$0$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$26.34K
    Gross profit$858.00K$636.00K$0$0$0$0-$26.34K
    Research and development$19.60M$41.51M$53.54M$40.69M$26.91M$17.63M$11.37M
    Operating income-$33.06M-$60.50M-$78.93M-$67.88M-$45.65M-$25.30M-$17.64M
    Net income-$8.98M-$57.77M-$74.56M-$66.65M-$47.01M-$26.45M-$17.63M
    EBITDA-$10.77MN/AN/AN/A-$45.44M-$25.00M-$17.39M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$212.00K$222.00K$212.00K$212.00K$212.00K$38.00K$299.00K$299.00K$0$228.00K
    Gross profit$0$0$212.00K$222.00K$212.00K$212.00K$212.00K$38.00K$299.00K$299.00K$0$114.00K
    Operating income-$3.42M-$5.65M-$8.73M-$6.41M-$6.92M-$10.06M-$9.67M-$11.61M-$12.07M-$17.04M-$19.79M-$21.11M
    Net income-$2.73M$43.66M-$8.28M-$5.85M$16.02M-$9.70M-$9.44M-$11.04M-$11.47M-$16.24M-$19.03M-$20.24M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $94.00K by $31.28M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$62.26M$68.11M$115.62M$180.44M$182.19M$141.86M$21.61M
    Current assets$61.25M$67.84M$114.79M$179.50M$180.87M$141.26M$20.92M
    Cash and equivalents$31.37M$13.90M$24.49M$56.96M$175.33M$140.23M$19.46M
    Total liabilities$4.30M$6.45M$9.44M$11.12M$6.58M$5.86M$4.75M
    Short-term debt$94.00K$154.00K$219.00K$181.00KN/AN/AN/A
    Shareholder equity$57.96M$61.65M$106.18M$169.32M$175.60M$136.00M$16.86M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$95.58M$98.06M$54.47M$62.26M$67.66M$51.00M$57.98M$68.11M$79.01M$92.43M$99.36M$115.62M
    Total liabilities$3.28M$3.57M$4.20M$4.30M$4.63M$5.04M$3.91M$6.45M$8.19M$12.41M$10.20M$9.44M
    Cash and equivalents$90.69M$92.85M$41.30M$31.37M$32.12M$9.45M$14.78M$13.90M$25.32M$16.67M$19.30M$24.49M
    Shareholder equity$92.30M$94.50M$50.28M$57.96M$63.03M$45.96M$54.07M$61.65M$70.82M$80.02M$89.16M$106.18M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$29.81M-$49.28M-$60.27M-$57.28M-$45.53M-$22.04M-$15.03M
    Capital expenditures$0$0$12.00K$54.00K$333.00K$137.00K$188.00K
    Free cash flow-$29.81M-$49.28M-$60.28M-$57.34M-$45.87M-$22.18M-$15.21M
    Share repurchases$0$268.00K$139.00K$693.00K$3.23M$319.00KN/A
    Investing cash flow$47.27M$33.49M$27.66M-$112.17M-$2.33M-$2.07M-$188.00K
    Financing cash flow$16.00K$5.20M$143.00K$51.08M$82.97M$144.89M$31.57M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.28M$45.92M-$7.98M-$4.68M-$6.55M-$8.38M-$10.21M-$9.86M-$13.54M-$10.42M-$15.46M-$11.64M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$0$12.00K
    Free cash flowN/AN/A-$7.98M-$4.68M-$6.55M-$8.38M-$10.21M-$9.86M-$13.54M-$10.42M-$15.46M-$11.66M
    Last 12 quarters

    Frequently Asked Questions About RLYB

    What is Rallybio's annual revenue?

    Rallybio reported revenue of $858.00K for the fiscal year ended Dec 31, 2025.

    How fast is Rallybio's revenue growing?

    Revenue was up 34.9% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Rallybio profitable?

    No. Rallybio reported net income of -$8.98M for the fiscal year ended Dec 31, 2025, with a net margin of -1046.4%.

    How much free cash flow does RLYB generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$29.81M minus capital expenditures of $0 produced free cash flow of -$29.81M.

    How much debt does Rallybio have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $94.00K and cash and equivalents of $31.37M.